CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Switching from Reference to Biosimilar Insulin Lispro for Patients with Diabetes Mellitus Type 1 or 2

Last updated: February 24, 2021
Project Number: RB1554-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness of switching from reference to biosimilar insulin lispro in adult or pediatric patients with diabetes mellitus (type 1 or 2)?

Key Message

One randomized controlled trial was identified regarding the clinical effectiveness of switching from reference to biosimilar insulin lispro in adult or pediatric patients with diabetes mellitus (type 1 or 2).